Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
BioXcel Therapeutics, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
BioXcel Therapeutics completed a registered direct offering on March 10, 2026, raising capital by selling 2,480,294 shares of common stock with accompanying warrants at $1.739 per unit. This equity financing supports the company's R&D and operational initiatives.
Key Takeaways
BioXcel raised approximately $4.31 million through the sale of 2,480,294 shares and warrants at $1.739 per unit
The registered direct offering indicates the company is pursuing equity financing rather than debt to fund operations and research
2 more takeaways